Journal list Promote Sponsor
verified SJR 0,814 · Q3 • database Scopus / SJR & Web of Science indexed
Immunity, inflammation and disease
United Kingdom · John Wiley and Sons Inc
workspace_premium Q3 — Immunology visibility_off Single blind Peer Review lock_open Open Access

Immunity, inflammation and disease

Immunity, inflammation and disease is a journal indexed in SJR in Immunology and Immunology and Allergy with an H index of 38. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on immunology, imaging, allergy, autoimmunity. It has an SJR impact factor of 0,814 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,814.

Publisher: John Wiley and Sons Inc
Category: Immunology
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Author guidelines
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
0,814 Q3
H-index 38
Acceptance rate pie_chart
39%
Source Acceptance_Rate
Time to publication hourglass_top
8 weeks
Field Average_time_publication_weeks
Publication cost (APC) payments
1.800 € Open Access
Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,814

H-index

38

Docs (year)

342

Docs 3y

695

Total refs

16935

Cites 3y

2076

Citable 3y

678

Cites/Doc 2y

2.81

Ref/Doc

49.52

Immediate OA

1800 €

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

FAQs